MRI-Targeted and TRUS Biopsies Have Similar Detection Rates for Prostate Cancer

According to research now published in JAMA Oncology, magnetic resonance imaging (MRI) with targeted biopsy (MRI-targeted biopsy) was shown to be just as effective at detecting prostate cancer compared with systematic 12-core transrectal ultrasonography (TRUS) biopsy. For this multicenter, prospective, randomized study, led by Laurence Klotz, MD, FRCSC, affiliate scientist at Sunnybrook Health Sciences Centre of the University of Toronto, 453 biopsy-naive patients with clinically suspected prost...

Pembrolizumab Still Effective After Five Years for Advanced Non-Small Cell Lung Cancer

Results of the KEYNOTE-010 study (NCT01905657) have shown that pembrolizumab is more effective than docetaxel for patients with previously treated, advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% and ≥1%. However, what do the results look like after long-term follow-up? According to a study presented this past weekend at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, pembroli...

Pathogenesis May Impact Survival Outcomes for Sinonasal Squamous Cell Carcinoma

The prognosis for sinonasal squamous cell carcinoma (SCC) is dismal, with the 5-year overall survival rate estimated to be around 30% to 55%. Sinonasal SCC pathogenesis can result from either de novo or inverted papillomas (IPs)—benign, aggressive neoplasms of the nasal cavity or paranasal sinuses. However, there is little research on whether or not the pathogenesis of sinonasal SCC has an impact on patient outcomes. According to a study recently published in JAMA Otolaryngology-Head & Neck ...

Kohei Shitara, MD: Fam-Trastuzumab Deruxtecan-Nxki for Gastric Cancer

Fam-trastuzumab deruxtecan-nxki (Enhertu®, Daiichi Sankyo) has recently been FDA approved for the treatment of adult patients with locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal adenocarcinoma previously treated with a trastuzumab-based regimen. In this interview with i3 Health, Kohei Shitara, MD, Chief of the Department of Gastrointestinal Oncology at the National Cancer Center Hospital East in Kashiwa, Japan, and lead investigator of the phase 3 DESTINY-Gastric01 trial, on which the approval was based, shares his insights on this approval, on the challenges of treating this patient population, and on the future of treatment for patients with gastric or gastroesophageal adenocarcinoma.

Renal Cell Carcinoma: Subtype, Site of Metastasis Impacts Survival

There are over a dozen histologic variants of renal cell carcinoma (RCC); therefore, each tumor can vary widely based on genetic, pathologic, and clinical characteristics. The most common histologic variants of RCC include clear cell RCC, papillary RCC, and chromophobe RCC. In a recent study, results of which are now published in JAMA Network Open, researchers found that disease spread for metastatic RCC may vary based on histologic variant, and the location of disease spread is associated with ...


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.